Literature DB >> 2364019

Attenuation of HIV-1 infectivity by an inhibitor of oligosaccharide processing.

D Dedera1, N Vander Heyden, L Ratner.   

Abstract

A series of inhibitors of trimming glucosidases and mannosidases were examined for antiviral activity toward HIV-1. N-butyl deoxynojirimycin (N-buDNJ) was found to be the most potent agent studied. Treatment of acutely infected lymphoid cells with 2.0 mM N-buDNJ reduced virus yield more than 90%, without affecting cell growth. Though lower concentrations of N-buDNJ (0.002-0.2 mM) did not affect HIV-1 production, there was complete inhibition of syncytia formation. Treatment of chronically infected lymphoid cells with 0.1-1.0 mM N-buDNJ resulted in no significant change in virus production, but 80% reduction of infectivity. The attenuation in HIV-1 infectivity was due at least partially to diminished binding to CD4+ lymphoid cells. Chronically infected lymphoid cells treated with 0.02-1.0 mM N-buDNJ for at least 3 days were markedly impaired in their ability to form syncytia with uninfected lymphoid cells. N-buDNJ treatment of HIV-1 infected cells resulted in both a reduction in the cell surface envelope proteins, and an increase in their apparent molecular weight. These results show that N-buDNJ can be used to impair the infectivity of HIV-1 without significant toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2364019     DOI: 10.1089/aid.1990.6.785

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage.

Authors:  D Dedera; R L Gu; L Ratner
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.

Authors:  R A Ogert; M K Lee; W Ross; A Buckler-White; M A Martin; M W Cho
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Demonstration of two distinct cytopathic effects with syncytium formation-defective human immunodeficiency virus type 1 mutants.

Authors:  D Dedera; L Ratner
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

Authors:  P B Fischer; M Collin; G B Karlsson; W James; T D Butters; S J Davis; S Gordon; R A Dwek; F M Platt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120.

Authors:  B D Hansen; P L Nara; R K Maheshwari; G S Sidhu; J G Bernbaum; D Hoekzema; M S Meltzer; H E Gendelman
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells.

Authors:  D L Taylor; M S Kang; T M Brennan; C G Bridges; P S Sunkara; A S Tyms
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

8.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120.

Authors:  P B Fischer; G B Karlsson; T D Butters; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure.

Authors:  P B Fischer; G B Karlsson; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 10.  Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus.

Authors:  Joanna L Miller; Beatrice E Tyrrell; Nicole Zitzmann
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.